Show Chwan Health Care System joins hands with Novotech to accelerate the quality of international clinical trials of new drugs

Written by Reporter: Li Lin Ai | Global Bio

Show Chwan Health Care System announced that it has signed a Memorandum of Understanding (MOU) with Novotech, a clinical research organization (CRO) in the Asia-Pacific region. It will use Novotech’s experience in planning clinical trials to target Changhua and the introduction of new clinical trial cases in Tainan, which will help doctors and patients get in touch with the latest treatment technologies and shorten the development period of new drugs.

Show Chwan Health Care System Chief Operating Officer Chen Xiuzhu said that Show Chwan Health Care System is committed to improving clinical research capabilities and medical service quality, and hopes to become one of the large-scale clinical trial research and execution units in China. The IRB Human Trial Committee and the HRPC Trial Research Subject Protection Center ensure that subjects receive the most complete protection during their participation in new drug clinical trials.  

Chief Operating Officer Chen Xiuzhu further said that in order to strengthen the development of the hospital in the field of clinical trials, Show Chwan Health Care System is also actively establishing partnerships with a number of internationally renowned pharmaceutical companies or related industries, including Taiwan’ AstraZeneca and BeiGene. In addition to striving for excellence, this cooperation with Novotech will also focus on the development of clinical trials and educational courses. 

Yooni Kim, Managing Director of Asia Pacific, Novotech, said she appreciated the opportunity to partner with Show Chwan Health Care as a clinical trial partner. Novotech has more than 5,000 clinical trial projects under its belt, ranging from Phase I to Phase IV trials and bioequivalence studies. To date, Novotech has successfully conducted more than 600 clinical trials in Taiwan and has extensive experience in Phase I and Phase II clinical trials (approximately 34%).

Director Kim said Novotech's clients primarily include biotechnology and small to mid-size pharma companies conducting clinical trials in the Asia-Pacific region, the U.S., and Europe. With over 3,000 employees and 34 offices worldwide, we provide clinical development services across all trial phases. Our operations adhere to the highest standards of ICH-GCP and global regulatory bodies, supported by an ISO9001-certified quality management system. Our professional team has extensive therapeutic experience across various disease areas. We believe this collaboration with Show Chwan will help drive the development and application of new drugs, accelerating their research and market entry, ultimately offering more treatment opportunities for patients."

(Report/ Li Lin Ai)

(Photo by reporter Lin Mingyou)